Monitor the November 4 shareholder meeting results for approval of the three proposals, which are prerequisites for the consolidation and the merger. The merger timeline remains contingent on these approvals.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $1.68entry
- T+1 · 13d ago +4.17%α +2.51% · $1.75
- T+5 · 7d ago −7.38%α −6.79% · $1.56
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed announced a 1-for-10 share consolidation conditional on shareholder approval of three proposals at the November 4, 2026 meeting. The consolidation is a procedural step to facilitate the pending merger with Mentari Therapeutics, reducing outstanding shares from 5,493,735 to approximately 549,374. No changes to deal terms or financials were disclosed.
Key Financial Metrics
Key Facts
- InMed announced a 1-for-10 share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.
- The consolidation is conditional on shareholder approval of the Nasdaq Share Issuance Proposal, Return of Capital Proposal, and Redomestication Proposal at the November 4, 2026 meeting.
- The consolidation is expected to be completed after market close on November 4, 2026, with post-consolidation shares trading on Nasdaq on November 5, 2026.
- This is a procedural step in the previously announced merger with Mentari Therapeutics, with no changes to deal terms or financials.
Financial Impact
No direct financial impact; share consolidation reduces share count from 5,493,735 to ~549,374 but does not change shareholder percentage ownership or company value.
Risk Factors
- Shareholder approval of the three proposals is required; failure to obtain approval would prevent the consolidation and could delay or jeopardize the merger.
- The consolidation is a reverse stock split that may affect liquidity and trading patterns, though it does not change fundamental value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-443834 |
| Document: 0001193125-26-443834-index-headers.html | 0001193125-26-443834 |
| Document: 0001193125-26-443834-index.html | 0001193125-26-443834 |
| Document: 0001193125-26-443834.txt | 0001193125-26-443834 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Viewing Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers